News

The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures, and clinical research.

Intergalactic's non-viral gene therapy platform is designed to overcome limitations of standard adeno-associated virus (AAV) gene therapy technologies.

Gonzalez shared that the ZETA-1 trial results demonstrate the potential of APX3330 to slow disease progression as well as highlight its favorable safety profile in the diabetic patient population.

The two-hour event will share details on the company’s clinical programs for retina diseases through formal presentations and a live Q&A session.

The investigators have developed a clinically robust HH-SECTR system, which has a modular aluminum probe design and micrometer-scale mechanical stability.

The severity and duration of gene therapy–associated uveitis correlated with increasing vector dose.

The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD.

The study's findings demonstrate the accuracy and feasibility of using machine learning models for identifying diabetic retinopathy (DR) progression developed using UWF images.

Get caught up on the approvals and hear directly from Kaushal Solanki, PhD, Founder and CEO of Eyenuk.

A single, consistent modality leads to better geographic atrophy tracking.

The retina is a peripheral part of the central nervous system and shares many similarities with cerebral brain matter.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

The study will include 100 patients with the aim of determining effective and ineffective standards of eye injections for AMD to better personalize future medical evaluations.

The certification will allow 20/20 Onsite to make clinical trials more accessible to patients nationwide and expand site options for sponsors while maintaining performance and data collection standards, including BCVA and DR testing.

As a nonsteroid treatment, RG6179 could open new methods for controlling inflammation with fewer adverse effects.

In-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.

This phase will evaluate UNITY’s UBX1325 (foselutoclax) in a head-to-head comparison with aflibercept for the treatment of diabetic macular edema (DME).

How AI tools can drive early detection of diabetic eye conditions.

Modern Retina is looking back at the first half of 2023 as we explore the role of AI in the retinal field in anticipation of the changes to come.

Real-world patients often fail to achieve and retain the visual acuity results observed in clinical trials for anti–VEGF-A therapy. Broader therapeutic inhibition of additional angiogenic factors VEGF-C and VEGF-D could change that.

Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.

New treatment options enhance patient visual outcomes and reduce treatment burdens.

Antimicrobial resistance is resistance to multiple classes of antibiotics, which makes it extremely challenging to treat infections caused by such organisms.

Artificial intelligence (AI) is going to be highly instrumental in patient care in all medical specialties and will be highly relevant in eye care.

EyeBio has begun the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

Jorge L. Alió, MD, PhD, FEBOphth, shared his pearls situations in which a patient presents with a cataract and corneal opacity at the European Society of Ophthalmology Conference, Prague.

The open source article reports on the anti-inflammatory compound and its potential to treat retinal diseases.

This approval will allow Belite Bio to initiate the phase 3 clinical trial in South Korea, also known as the DRAGON study.